🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nashik
Clinical trial register · India

Clinical Trials in Nashik

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1123 matching records held by the registry are in this view. Synced 21 Sep 2026, 03:16 UTC
1123
Studies in scope
all four open statuses
610
Recruiting now
open to new participants
222
Lead sponsors
across recruiting studies
Top sites
New Delhi 13 Pune 11 Mumbai 11 Kolkata 10 Surat 10
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca29 Eli Lilly and Company9 Novartis Pharmaceuticals8 Pfizer8 Janssen Research & Development, LLC5 Clear sponsor filter
Site location
New Delhi13 Pune11 Mumbai11 Kolkata10 Surat10
All 39 locations
Target enrolment
to
8 of 1123 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Recruiting
A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF
NCT07653100Respiratory Syncytial Virus (RSV)
Pfizer
Phase 3
540
Visakhapatnam, Bangalore, Belagavi, Nashik, Dwarka, New Delhi, Jaipur, Chengalpattu
2026-06-22
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
Pfizer
Phase 3
1,410
Surat, Vadodara, Gurugram, Bangalore, Belagavi, Kottayam, Nagpur, Nashik
2026-01-06
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965Breast Cancer
Pfizer
Phase 3
400
Surat, Bengaluru, Nashik, Pune
2025-08-05
Recruiting
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
NCT06641466Menstrual Migraine
Pfizer
Phase 3
723
Guntur, Ahmedabad, Mangaluru, Mumbai, Nagpur, Nashik, Ajmer, Lucknow
2025-03-11
Active, closed
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637Breast Cancer
Pfizer
Phase 3
1,035
Surat, Gurugram, Bangalore, Mumbai, Nashik, Pune, Thane, New Delhi
2025-01-06
Active, closed
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
NCT06616194Migraine
Pfizer
Phase 3
200
Gurugram, Mangalore, Nashik, New Delhi
2024-11-15
Active, closed
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
NCT05654623Advanced Breast Cancer
Pfizer
Phase 3
624
Gurgaon, Mumbai, Nashik, Thane, New Delhi, Kolkata
2023-03-03
Recruiting
A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
NCT05431088Sickle Cell Disease
Pfizer
Phase 2/3
389
Raipur, Surat, Vadodara, Nashik, New Delhi, Bhubaneswar
2022-09-22
Rows per page Showing 1–8 of 8
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-india/city/nashik

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.